Surface decoration of gold nanoparticles with thermoresponsive polymers endows a temperature tunable colloidal system switchable for enhanced intracellular up-take. Gold nanoparticles (AuNP, 18 ± 11 nm-diameter) produced by laser ablation synthesis in liquid solution were surface coated with thermoresponsive thiol terminated poly-N-isopropylacrylamide-co-acrylamide co-polymer possessing a lower critical solution temperature (LCST) at 37 °C. Under selected conditions about 3800 polymer chains were conjugated per particle. The polymer coated nanoparticles were found to display thermosensitive properties, as in solution they exhibited reversible aggregation/deaggregation above and below the LCST, respectively. Cell culture studies showed that the polymer decorated AuNP were located into human breast adenocarcinoma MCF7 cells treated at 40 °C (12000 AuNP/cell) with more than 80-fold greater up-take compared to cells treated at 34 °C with the same particles (140 AuN/cell). This difference is attributable to a ‘switching’ of the polymer coating to a globule state at 37 °C and an increased hydrophobicity of the particles with a simultaneous loss of the ‘stealth’ properties of the polymer coating. By contrast, cell up-take of uncoated AuNP (about 6000 AuNP/cell) did not depend on the incubation temperature. These data show that good control of the AuNP cell up-take can be obtained with the new polymer-gold nanoconjugates, and suggest that these systems might find use for targeting cellsin vitro by a small temperature change or in vivo in body sites, such as inflamed or tumour tissues, where a temperature variation is already present.

Liposomes have been one of the most exploited drug delivery systems in recent decades. However, their large-scale production with low batch-to-batch differences is a challenge for industry, which ultimately delays the clinical translation of new products. We have investigated the effects of formulation parameters on the colloidal and biopharmaceutical properties of liposomes generated with a thin-film hydration approach and microfluidic procedure. Dexamethasone hemisuccinate was remotely loaded into liposomes using a calcium acetate gradient. The liposomes produced by microfluidic techniques showed a unilamellar structure, while the liposomes produced by thin-film hydration were multilamellar. Under the same remote loading conditions, a higher loading capacity and efficiency were observed for the liposomes obtained by microfluidics, with low batch-to-batch differences. Both formulations released the drug for almost one month with the liposomes prepared by microfluidics showing a slightly higher drug release in the first two days. This behavior was ascribed to the different structure of the two liposome formulations. In vitro studies showed that both formulations are non-toxic, associate to human Adult Retinal Pigment Epithelial cell line-19 (ARPE-19) cells, and efficiently reduce inflammation, with the liposomes obtained by the microfluidic technique slightly outperforming. The results demonstrated that the microfluidic technique offers advantages to generate liposomal formulations for drug-controlled release with an enhanced biopharmaceutical profile and with scalability.

In this review, we discuss the use of oncolytic viruses and checkpoint inhibitors in cancer immunotherapy in melanoma, with a particular focus on combinatory therapies. Oncolytic viruses are promising and novel anti-cancer agents, currently under investigation in many clinical trials both as monotherapy and in combination with other therapeutics. They have shown the ability to exhibit synergistic anticancer activity with checkpoint inhibitors, chemotherapy, radiotherapy. A coupling between oncolytic viruses and checkpoint inhibitors is a well-accepted strategy for future cancer therapies. However, eradicating advanced cancers and tailoring the immune response for complete tumor clearance is an ongoing problem. Despite current advances in cancer research, monotherapy has shown limited efficacy against solid tumors. Therefore, current improvements in virus targeting, genetic modification, enhanced immunogenicity, improved oncolytic properties and combination strategies have a potential to widen the applications of immuno-oncology (IO) in cancer treatment. Here, we summarize the strategy of combinatory therapy with an oncolytic vector to combat melanoma and highlight the need to optimize current practices and improve clinical outcomes.